We show that activated Wnt signalling is correlated with immune suppression in primary PC, and suggest that activated Wnt/β-catenin, MMR, high INIF and the CD8+/FOXP3+ ratio should be explored as predictive biomarkers for immunotherapeutics in prostate cancer. The gene discussed is FOXP3; the disease is pachyonychia congenita.